Kemadrin

Procyclidine, the active ingredient in Kemadrin, is an anticholinergic (muscarinic antagonist) presented as an oral formulation for oral use. It is employed to alleviate motor symptoms in Parkinson’s disease and to manage drug‑induced extrapyramidal side effects in patients receiving antipsychotic therapy. It is approved for use in the European Union and is prescribed by neurologists and psychiatrists.

GNH USA supplies Kemadrin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required.

Procyclidine is used to treat movement disorders that arise from excessive cholinergic activity in the central nervous system.

- Parkinsonian tremor and rigidity: reduces tremor amplitude and muscle stiffness in patients with Parkinson’s disease. - Drug‑induced dystonia: alleviates sustained muscle contractions caused by antipsychotic medications. - Akathisia: diminishes restlessness and urge to move associated with dopamine‑blocking agents. - Antipsychotic‑related tremor: lessens fine tremor that develops during neuroleptic therapy.

Procyclidine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dry mouth: reduced salivation leading to thirst and difficulty swallowing. - Blurred vision: difficulty focusing at near distances. - Constipation: slowed gastrointestinal motility. - Urinary retention: difficulty initiating urination. - Nausea: upset stomach and possible vomiting. - Drowsiness: increased sleepiness or fatigue.

Serious or Rare Side Effects: - Confusion or delirium: acute changes in mental status. - Tachycardia: rapid heart rate that may require monitoring. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hallucinations: visual or auditory disturbances.

When prescribing Procyclidine, clinicians should consider several safety precautions to minimize risk. - Assess renal and hepatic function: adjust use in patients with severe impairment. - Monitor for anticholinergic burden: avoid concurrent use with other strong anticholinergics. - Evaluate cognitive status: patients with dementia may experience worsening confusion. - Review cardiac history: tachycardia or arrhythmias may be exacerbated. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture.

Procyclidine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other anticholinergic agents: additive anticholinergic effects may cause severe dryness, urinary retention, or cognitive impairment. - QT‑prolonging drugs: combined use can increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Dopaminergic medications: may reduce therapeutic benefit of Procyclidine. - CNS depressants (e.g., benzodiazepines): enhanced sedation and dizziness. - Antihistamines with anticholinergic activity: increased likelihood of dry mouth and blurred vision.